Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
February 1, 2026
Approximately 5 minutes
Reporting Field Safety Corrective Actions to HSA in Singapore
Reporting Field Safety Corrective Actions to HSA in Singapore
1. Overview
Manufacturers are required to report Field Safety Corrective Actions (FSCA) to the Health Sciences Authority (HSA) in Singapore promptly when corrective measures are taken to address risks associated with medical devices already on the market. This includes submitting the Field Safety Notice (FSN) and relevant details. Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
2. Reporting Timeline
Report the FSCA to HSA no later than 2 working days after the FSCA is initiated or when the need for corrective action is identified. Early reporting is encouraged to facilitate timely risk communication. Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
3. Required Information for Reporting
The FSCA report must include:
- Manufacturer details (name, contact information)
- Device details (brand name, model, catalogue number, affected serial/lot numbers)
- Reason for the FSCA (description of the issue, risk assessment)
- Type of corrective action (recall, design change, software update, labelling change, etc.)
- Field Safety Notice (FSN) or equivalent communication
- Distribution information in Singapore (consignees, quantities supplied)
Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
4. Submission Method
- Submit the report electronically via the HSA online portal or email to the Medical Devices Branch.
- Attach the FSN and any supporting documents (e.g., risk analysis, test reports).
- For overseas manufacturers, the authorised representative in Singapore may assist with submission.
Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
5. Field Safety Notice (FSN) Requirements
- The FSN must be clear, concise, and in English.
- Include urgency level, problem description, risk to patients/users, recommended actions, and reply form.
- Manufacturers must distribute the FSN to all relevant consignees in Singapore and provide HSA with proof of distribution.
Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
6. Follow-up and Monitoring
- HSA may request additional information or clarification.
- Manufacturers must monitor the effectiveness of the FSCA and submit follow-up reports if required.
- Provide updates on the progress of the corrective action and closure of the FSCA.
Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
7. Important Notes
- Timely and complete reporting helps HSA coordinate risk mitigation efforts.
- Non-compliance with reporting requirements may lead to regulatory action.
- Last updated: 31 Dec 2018. Source: https://www.hsa.gov.sg/medical-devices/field-safety-corrective-action/how-to-report
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
Adverse Event Reporting for Medical Devices in Singapore
Healthcare professionals, manufacturers, importers, and suppliers in Singapore are required to report serious adverse events involving medical devices to HSA within specified timelines to support post-market safety monitoring.
Approximately 5 minutes
When to Report Field Safety Corrective Actions in Singapore
Manufacturers must report Field Safety Corrective Actions (FSCA) to HSA when a device presents an unacceptable risk or when corrective measures are needed to reduce risk, including recalls, design modifications, and labelling changes.
Approximately 5 minutes
Types of Field Safety Corrective Actions for Medical Devices in Singapore
Field Safety Corrective Actions in Singapore include recalls, design modifications, software updates, labelling changes, and user advice to mitigate unacceptable risks associated with marketed medical devices.